$500m upfront (presumably split two way) would be amazing. Do you really think this is possible?
I was thinking an upfront of $100m would be very nice with minimum quarterly milestones, and if it is Glaxo, these minimum milestones could be negotiated on Relenza as well (certainly up until Lani is approved for sale).
If we are anywhere near $500m, then with their $250m share, Biota would instantly propel itself a couple of rungs higher than I would have expected.
BTA Price at posting:
$2.29 Sentiment: LT Buy Disclosure: Held
